TIBER CREEK GROUP

Lobbying for PHRMA

Filing 1st Quarter - Amendment

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $110,000.00 income · posted Sep 30, 2025

Lobbying activity 3

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform.

Trade (domestic/foreign)

Issues related to intellectual property protections.

Health Issues

Issues related to the 340B Program - Public Health Service Act (PL 78-410).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.